Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive metastatic breast cancer.
This statement is based on a regulatory approval from the Health Service Executive:
HER2 positive metastatic breast cancer (MBC).